Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Journal Article (Journal Article)

PURPOSE: This pilot study was performed to test our ability to administer neratinib monotherapy before clinically recommended craniotomy in patients with HER2-positive metastatic breast cancer to the central nervous system, to examine neratinib's central nervous system penetration at craniotomy, and to examine postoperative neratinib maintenance. PATIENTS AND METHODS: Patients with HER2-positive brain metastases undergoing clinically indicated cranial resection of a parenchymal tumor received neratinib 240 mg orally once a day for 7 to 21 days preoperatively, and resumed therapy postoperatively in 28-day cycles. Exploratory evaluations of time to disease progression, survival, and correlative tissue, cerebrospinal fluid (CSF), and blood-based analyses examining neratinib concentrations were planned. The study was registered at under number NCT01494662. RESULTS: We enrolled 5 patients between May 22, 2013, and October 18, 2016. As of March 1, 2019, patients had remained on the study protocol for 1 to 75+ postoperative cycles pf therapy. Two patients had grade 3 diarrhea. Evaluation of the CSF showed low concentrations of neratinib; nonetheless, 2 patients continued to receive therapy without disease progression for at least 13 cycles, with one on-study treatment lasting for nearly 6 years. Neratinib distribution in surgical tissue was variable for 1 patient, while specimens from 2 others did not produce conclusive results as a result of limited available samples. CONCLUSION: Neratinib resulted in expected rates of diarrhea in this small cohort, with 2 of 5 patients receiving the study treatment for durable periods. Although logistically challenging, we were able to test a limited number of CSF- and parenchymal-based neratinib concentrations. Our findings from resected tumor tissue in one patient revealed heterogeneity in drug distribution and tumor histopathology.

Full Text

Duke Authors

Cited Authors

  • Freedman, RA; Gelman, RS; Agar, NYR; Santagata, S; Randall, EC; Gimenez-Cassina Lopez, B; Connolly, RM; Dunn, IF; Van Poznak, CH; Anders, CK; Melisko, ME; Silvestri, K; Cotter, CM; Componeschi, KP; Marte, JM; Moy, B; Blackwell, KL; Puhalla, SL; Ibrahim, N; Moynihan, TJ; Nangia, J; Tung, N; Burns, R; Rimawi, MF; Krop, IE; Wolff, AC; Winer, EP; Lin, NU; Translational Breast Cancer Research Consortium (TBCRC),

Published Date

  • April 2020

Published In

Volume / Issue

  • 20 / 2

Start / End Page

  • 145 - 151.e2

PubMed ID

  • 31558424

Pubmed Central ID

  • PMC7035200

Electronic International Standard Serial Number (EISSN)

  • 1938-0666

Digital Object Identifier (DOI)

  • 10.1016/j.clbc.2019.07.011


  • eng

Conference Location

  • United States